Asset Retirement Obligations (Tables)

12 Months Ended

Dec. 31, 2021

Asset Retirement Obligation Disclosure [Abstract]

Asset Retirement Obligation Rollforward

The following table provides a rollforward of the nuclear decommissioning AROs reflected in Exelon’s Consolidated Balance Sheets from December 31, 2019 to December 31, 2021:

Nuclear decommissioning AROs as of December 31, 2019	$	10,504
Net increase due to changes in, and timing of, estimated future cash flows	1,022
Accretion expense	489
Costs incurred related to decommissioning plants	(93)
Nuclear decommissioning AROs as of December 31, 2020(a)	11,922
Net increase due to changes in, and timing of, estimated future cash flows	324
Accretion expense	503
Costs incurred related to decommissioning plants	(73)
Nuclear decommissioning AROs as of December 31, 2021(a)	$	12,676

__________

(a)Includes $72 million and $80 million as the current portion of the ARO as of December 31, 2021 and 2020, respectively, which is included in Other current liabilities in Exelon’s Consolidated Balance Sheets.

The following table provides a rollforward of the non-nuclear AROs reflected in the Registrants’ Consolidated Balance Sheets from December 31, 2019 to December 31, 2021:

	Exelon		ComEd		PECO		BGE		PHI		Pepco		DPL		ACE
Non-nuclear AROs as of December 31, 2019	$	460	$	129	$	28	$	23	$	57	$	41	$	12	$	4
Net increase (decrease) due to changes in, and timing of, estimated future cash flows	7		—		2		1		1		(3)		2		2
Development projects	1		—		—		—		—		—		—		—
Accretion expense(a)	16		1		1		1		1		1		—		—
Asset divestitures	(4)		—		—		—		—		—		—		—
Payments	(9)		(1)		(2)		(2)		—		—		—		—
AROs reclassified to liabilities held for sale	(10)		—		—		—		—		—		—		—
Non-nuclear AROs as of December 31, 2020	461		129		29		23		59		39		14		6
Net increase due to changes in, and timing of, estimated future cash flows	31		15		—		2		10		5		2		3
Accretion expense(a)	18		4		1		1		1		1		—		—
Asset divestitures	(19)		—		—		—		—		—		—		—
Payments	(11)		(2)		(1)		—		—		—		—		—
AROs previously held for sale	10		—		—		—		—		—		—		—
Non-nuclear AROs as of December 31, 2021	$	490	$	146	$	29	$	26	$	70	$	45	$	16	$	9

__________

(a)For ComEd, PECO, BGE, PHI, and Pepco, the majority of the accretion is recorded as an increase to a regulatory asset due to the associated regulatory treatment.